Marc Scheineson comments on the U.S. Food and Drug Administration’s recent draft guidance on the benefit and risk assessment for opioids.
In the News
July 17, 2019
The Pink Sheet | Comparative Confusion: What Does FDA Intend for Opioid Comparative Efficacy Data?
Media Contact